Risk and Clinical Consequences of Low Count Monoclonal B-cell Lymphocytosis (LC MBL)

Launched by UNIVERSITY OF HAIFA · May 10, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a condition called low count monoclonal B-cell lymphocytosis (LC MBL), which affects some people over the age of 40. LC MBL is a precursor to chronic lymphocytic leukemia (CLL) and is characterized by an unusual number of specific cells in the blood. The goal of the study is to find out more about the immune system and genetic factors that might increase the risk of developing serious health issues, like infections or cancers, in people with LC MBL. The research will include a diverse group of individuals from various backgrounds in Israel to gather information that has not been widely studied before.

To participate in this trial, individuals must be over 40 years old and should not have any lymphoproliferative disorders, which are conditions where certain types of blood cells grow abnormally. While the study is not yet recruiting participants, those who join can expect to contribute to important research that could help improve understanding of LC MBL and its potential effects on health. This study aims to provide valuable insights that could benefit many people in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Individuals over the age pf 40
• Exclusion Criteria:
• • Individuals with lymphoproliferative disorder